FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention describes compounds of general formula (I) or their pharmaceutically acceptable salts which are modulators of the CCR2 receptor.
(I).
EFFECT: they can be used in pharmaceutical compositions for treating a CCR2-mediated disease or disorder, in methods of treating a mammal suffering from or prone to disease or disorder, selected from the group consisting of renal fibrosis, polycystic kidney disease, rheumatoid arthritis, atopic dermatitis, psoriasis, nephropathy, pancreatic cancer and non-alcoholic steatohepatitis (NS), as well as methods of inhibiting CCR2 receptor-mediated cell chemotaxis, involving contacting mammalian white blood cells with a modulating CCR2 receptor.
52 cl, 2 dwg, 29 ex
Title | Year | Author | Number |
---|---|---|---|
PRODRUGS OF CONJUGATED BICYCLIC C5aR ANTAGONISTS | 2019 |
|
RU2794327C2 |
DIARYL-SUBSTITUTED 6,5-CONJUGED CYCLIC COMPOUNDS AS C5aR INHIBITORS | 2018 |
|
RU2796983C2 |
6-5 CONDENSED RINGS AS C5a INHIBITORS | 2018 |
|
RU2780338C2 |
PIPERIZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | 2005 |
|
RU2369604C2 |
CXCR7 ANTAGONISTS | 2013 |
|
RU2649004C2 |
DIAZOLE LACTAMS | 2013 |
|
RU2666730C2 |
THIOPHENYL AND PYRROLYL AZEPINES AS SEROTONIN 5HT RECEPTOR LIGANDS AND USE THEREOF | 2007 |
|
RU2434872C2 |
5-5 CONDENSED RINGS AS C5a INHIBITORS | 2018 |
|
RU2780322C2 |
ANTAGONISTS OF CHEMOKINE RECEPTORS | 2013 |
|
RU2646762C2 |
2-OXINDOLE COMPOUNDS | 2017 |
|
RU2743747C2 |
Authors
Dates
2020-07-09—Published
2016-05-19—Filed